Wyeth Pharmaceuticals Donates Hemophilia Products to Summer Camps

Collegeville, Pa., (June 15,2005) — In keeping with its continued support of the hemophilia community, Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced the continuation of its product donation program for bleeding disorder summer camps. For the past 9 years, Wyeth has donated a supply of BeneFIX^® Coagulation Factor IX (Recombinant) and ReFacto^® Antihemophilic Factor (Recombinant) to summer camps for the bleeding disorder community across the country. In 2004, Wyeth supplied 24 camps with donated product.

"We are pleased to support summer camps in the bleeding disorder community with product donations, and to see our products contribute to a rewarding and healthy experience for children attending camp," said Robert J. Dufour, Assistant Vice President & Global Business Manager — Hemophilia at Wyeth.

Wyeth is the founding and exclusive sponsor of the North American Camping Conference of Hemophilia Organizations (NACCHO), conducted by the Hemophilia Association, Inc. of Phoenix, Arizona. NACCHO is the only conference for community volunteers who conduct bleeding disorder summer camps, and offers participants the opportunity to share best practices for summer camp.

Hemophilia is a rare, inherited blood clotting disorder for which there currently is no cure. People with hemophilia are deficient in one of the key proteins — either factor VIII (hemophilia A) or factor IX (hemophilia B) — that are vital in the clotting cascade to prevent bleeding. Both forms of hemophilia are characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. In the United States, nearly 4,000 people have hemophilia B and between 15,000 and 17,000 people have hemophilia A.

BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings.

BeneFIX is not indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X) nor the treatment of hemophilia A patients with inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation, nor the treatment of bleeding due to low levels of liver-dependent coagulation factors.

As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or tiredness. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur. BeneFIX may be contraindicated in patients with a known history of hypersensitivity to hamster protein. The accompanying diluent vial may contain dry natural rubber that may cause hypersensitivity reactions in persons with known or possible latex sensitivity.

About ReFacto
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions. The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto. Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see the Prescribing Information for BeneFix and ReFacto.

About Wyeth
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines, and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Back to News